A multicenter trial of alogliptin for the safety and efficacy on glycemic control in Japanese type 2 diabetic patients undergoing hemodialysis

A multicenter trial of alogliptin for the safety and efficacy on glycemic control in Japanese type 2 diabetic patients undergoing hemodialysis - Alogliptin in type 2 diabetic patients undergoing hemodialysis

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006082

Enrollment

Registered

2011-08-01

Start date

2011-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetic patients undergoing hemodialysis

Interventions

Observation span: 24 weeks Intervention: Alogliptin (Nesina) Dose: 6.25mg once daily

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Type 2 diabetic patients undergoing hemodialysis, treated with insulin

Exclusion criteria

Exclusion criteria: 1) Type 1 diabetic patients 2) Patients with insulin dose equal to or greater than 15 unit per day 3) Patients with liver disease 4) Patients with cancer disease 5) Patients with inflammatory disease 6) patients considered as inadequate by the principal investigator

Design outcomes

Primary

Measure	Time frame
Changes in QOL, plasma glucose, HbA1c and glycated alubmin levels(0, 4, 8, 12, 16, 20 and 24 weeks after starting of treatment)	—

Secondary

Measure	Time frame
C-peptide and glucagon levels(0 and 24 weeks after starting of treatment)	—

Countries

Japan

Contacts

Public ContactNaoshi Yoshida

Tokyo Women's Medical University Third Department of Medicine

yoshida@dmc.twmu.ac.jp03-3353-8111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026